Abiopharma

Indivior Notification

Viridian Therapeutics, Inc. - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

EUDA Integrates QB Utility Token to Create a Digital Health and Rewards Platform Across Its Healthcare Ecosystem

Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Have you lost money in Integer Holdings Corporation? Contact Robbins LLP for information about your rights against ITGR.

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Indivior Announces Inclusion in the S&P SmallCap 600® Index

Incyte Japan maakt de goedkeuring bekend van Zynyz® (retifanlimab) voor eerstelijnsbehandeling van anale kanker in een gevorderd stadium